PET3

PreclinicalSmall molecule

UUniversity of Aarhus

PET3 is one of 22 small molecule programs targeting Giant Cell Arteritis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Giant Cell ArteritisActive, not recruiting

Giant Cell ArteritisPreclinical

Active, not recruiting

Competition

Competitive Landscape

30 competitors in Giant Cell Arteritis

#DrugCompanyPhaseTrials

Cosentyx

Novartis

Phase 3

3 2

Orencia

Bristol-Myers Squibb

Phase 3

3 3

Rinvoq

AbbVie

Phase 3

1 4

Rayos

RRoxane Laboratories

Phase 3

6 5

Humira

CCelltrion

Phase 3

1 6

Kineret

SSwedish Orphan Biovitrum

Phase 3

1 7

Sirukumab

Johnson & Johnson

Phase 3

1 8

Treatment

GSK

Phase 3

1 9

Trexall

Alnylam Pharmaceuticals

Phase 2

3 10

Tremfya

Johnson & Johnson

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Giant Cell Arteritis1 trial

FDG Uptake in Large-Vessel Giant Cell Arteritis After Short-term, High-Dose Steroid Treatment

Completed·UUniversity of Aarhus··NCT03285945·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PET3. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PET3 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PET3. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Aarhus company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Aarhus

PET3

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Giant Cell Arteritis1 trial

References

Drug Info

Quick Facts

Related News